NASDAQ$HOLX
Hologic Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Hologic's financial results meaningfully exceeded guidance, driven by strong growth in base Diagnostics and Surgical franchises.
Hologic's Q3 2022 financial results exceeded expectations, with revenue of $1.003 billion and GAAP diluted EPS of $0.90. The company experienced a decrease in revenue compared to the prior year, primarily driven by lower international sales of COVID-19 assays and supply chain challenges in the Breast Health business. However, the base Diagnostics and Surgical franchises showed strong growth.
- Revenue of $1.003 billion decreased (14.2%) year over year, or (12.2%) in constant currency.
- GAAP diluted EPS was $0.90, while non-GAAP diluted EPS was $0.95, both significantly ahead of expectations.
- Global organic molecular diagnostics revenue, excluding COVID-19, grew over 20% in constant currency.
- The company increased full-year revenue and EPS guidance.
- Cash flow from operations remained very strong in the third quarter at $330.6 million.
Headline financials
Revenue & EPS history
Hologic · Revenue · Quarterly
$1B
Revenue by segment
Hologic · $1.28B total across 3 segments · Q3 2022
- Diagnostics$560M-15.8%43.8%
- Molecular Diagnostics$435M-18.8%34.1%
- Breast Health$283M-19.0%22.1%
Forward guidance
Hologic anticipates ongoing strength in its core Diagnostics and Surgical sectors during the fiscal fourth quarter, which is expected to offset supply chain challenges in the Breast Health division.
Tailwinds
- Continued strength in base Diagnostics business
- Continued strength in base Surgical businesses
- Expectations of supply chain headwinds in Breast Health business to be counterbalanced
- Company increased full-year revenue guidance
- Company increased full-year EPS guidance
Headwinds
- Revenue is expected to be between $840 million and $870 million, a decrease of (36.2%) to (33.9%).
- GAAP EPS is expected to be between $0.33 and $0.38, a decrease of (74.2%) to (70.3%).
- Non-GAAP EPS is expected to be between $0.60 and $0.65, a decrease of (62.7%) to (59.6%).
- Supply chain headwinds in Breast Health business
- Lower international sales of COVID-19 assays
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-0.5%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.1%
Avg return
30 days after
49%
35 / 72 earnings
Positive
+12.3%
Q3 2020
Best reaction
-11.4%
Q2 2012
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | +0.0% | -0.6% | +0.7% | |
| Q4 2025 | +0.1% | +0.1% | +0.9% | |
| Q3 2025 | +2.8% | +4.4% | +3.3% | |
| Q2 2025 | -5.6% | -3.2% | +8.5% | |
| Q1 2025 | -10.1% | -11.4% | -11.3% | |
| Q4 2024 | -4.3% | -4.3% | -6.6% | |
| Q3 2024 | +4.9% | +6.4% | +2.2% | |
| Q2 2024 | +0.3% | -0.2% | -3.3% | |
| Q1 2024 | -2.7% | -0.4% | -1.1% | |
| Q4 2023 | +5.7% | +5.4% | +0.1% | |
| Q3 2023 | -5.1% | -5.9% | -5.4% | |
| Q2 2023 | -2.4% | -2.6% | -8.3% | |
| Q1 2023 | +3.8% | +3.6% | -1.1% | |
| Q4 2022 | +10.8% | +12.4% | +13.8% | |
| Q3 2022 | +1.0% | +1.3% | -3.4% | |
| Q2 2022 | +1.2% | +3.4% | +9.8% | |
| Q1 2022 | +4.0% | +3.8% | +2.4% | |
| Q4 2021 | -3.3% | -5.9% | -0.3% | |
| Q3 2021 | +2.3% | +5.0% | +9.7% | |
| Q2 2021 | -9.1% | -9.9% | -13.4% | |
| Q1 2021 | +1.7% | +11.2% | -3.3% | |
| Q4 2020 | +6.6% | -5.0% | +1.7% | |
| Q3 2020 | +12.3% | +14.8% | -2.8% | |
| Q2 2020 | +2.9% | +2.6% | +8.9% | |
| Q1 2020 | -0.7% | -1.8% | -13.7% | |
| Q4 2019 | -4.0% | +8.8% | +10.3% | |
| Q3 2019 | -1.3% | -6.5% | -4.1% | |
| Q2 2019 | -0.1% | +0.7% | -5.1% | |
| Q1 2019 | +0.6% | -0.5% | +8.6% | |
| Q4 2018 | +4.9% | +1.2% | +3.7% | |
| Q3 2018 | -3.5% | -1.9% | -7.5% | |
| Q2 2018 | -6.9% | -6.8% | -3.9% | |
| Q1 2018 | -6.7% | -6.6% | -2.2% | |
| Q4 2017 | +0.4% | +2.9% | +8.1% | |
| Q3 2017 | -9.3% | -11.3% | -12.5% | |
| Q2 2017 | -4.3% | -5.1% | -2.0% | |
| Q1 2017 | -2.6% | -2.9% | +1.8% | |
| Q4 2016 | +4.3% | +8.5% | +6.3% | |
| Q3 2016 | +3.9% | +5.8% | +5.3% | |
| Q2 2016 | -10.0% | — | — | |
| Q1 2016 | -9.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +8.6% | — | — | |
| Q2 2015 | +2.1% | — | — | |
| Q1 2015 | +5.1% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | +2.1% | — | — | |
| Q2 2014 | +8.1% | — | — | |
| Q1 2014 | -5.9% | — | — | |
| Q4 2013 | -6.9% | — | — | |
| Q3 2013 | -0.2% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | -4.1% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -0.4% | — | — | |
| Q2 2012 | -11.4% | — | — | |
| Q1 2012 | +5.2% | — | — | |
| Q4 2011 | -4.0% | — | — | |
| Q3 2011 | -3.9% | — | — | |
| Q2 2011 | -0.6% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | +1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | -2.8% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q2 2009 | +2.9% | — | — | |
| Q4 2007 | +2.9% | — | — | |
| Q4 2009 | +2.9% | — | — | |
| Q3 2009 | -3.0% | — | — | |
| Q3 2008 | -3.0% | — | — | |
| Q4 2008 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro